Current understanding of AD pathophysiology and impact of amyloid beta-targeted treatments on biomarkers and clinical endpoints

Alzheimers Dement. 2022 Aug;18(8):1586. doi: 10.1002/alz.12769. Epub 2022 Aug 10.
No abstract available

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Amyloid beta-Peptides*
  • Biomarkers
  • Humans
  • tau Proteins

Substances

  • Amyloid beta-Peptides
  • Biomarkers
  • tau Proteins